Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
10.05
-0.21 (-2.05%)
Dec 11, 2025, 11:38 AM EST - Market open
CRBP Employees
Corbus Pharmaceuticals Holdings had 28 employees as of December 31, 2024. The number of employees increased by 9 or 47.37% compared to the previous year.
Employees
28
Change (1Y)
9
Growth (1Y)
47.37%
Revenue / Employee
n/a
Profits / Employee
-$2,411,143
Market Cap
186.21M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRBP News
- 19 hours ago - Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 - GlobeNewsWire
- 5 weeks ago - Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis - Seeking Alpha
- 5 weeks ago - Corbus Pharmaceuticals Announces Pricing of Public Offering - GlobeNewsWire
- 5 weeks ago - Corbus Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 7 weeks ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript - Seeking Alpha
- 7 weeks ago - Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 - GlobeNewsWire
- 3 months ago - FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma - GlobeNewsWire